Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corp (NY: CVM )

2.265 +0.015 (+0.67%)
Streaming Delayed Price Updated: 12:13 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corp

< Previous 1 2 3 4 5 Next >
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
From CEL-SCI Corporation
Via Business Wire
Why CEL-SCI Shares Are Shooting Higher Today
CEL-SCI Corporation (NYSE: CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Gainers Leju Holdings Limited (NYSE: LEJU) gained 103.7% to $7.25 in pre-market trading after jumping around 97% on Monday . 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension
Via Benzinga
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're getting into the biggest pre-market stock movers traders will want to keep an eye on Wednesday with the latest news! 
Via InvestorPlace
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. 
Via Benzinga
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in... 
Via Benzinga
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
Via Benzinga
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Why Pinterest Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket
Gainers Zovio Inc (NASDAQ: ZVO) rose 39.5% to $0.2449 in pre-market trading after gaining 7% on Thursday. 
Via Benzinga
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
From CEL-SCI Corporation
Via Business Wire
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month. 
Via Benzinga
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering... 
Via Benzinga
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.